{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:40:15Z","timestamp":1758937215661,"version":"3.44.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009812","name":"Princess Margaret Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009009","name":"Novartis Pharmaceuticals Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.leukres.2019.106285","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T12:30:02Z","timestamp":1575549002000},"page":"106285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-008X","authenticated-orcid":false,"given":"Christopher M.","family":"Hillis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4013-0956","authenticated-orcid":false,"given":"Nicholas L.","family":"Jackson Chornenki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Bence-Bruckler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambert","family":"Busque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvan","family":"Cote","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanda","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Kamel-Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn","family":"Savoie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Robert","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anargyros","family":"Xenocostas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2019.106285_bib0005","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","article-title":"Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia","volume":"23","author":"Cortes","year":"2009","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.leukres.2019.106285_bib0010","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1182\/blood-2007-03-079871","article-title":"Use of theraputic drug monitoring in CML patients on imatinib","volume":"110","author":"P.S","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2019.106285_bib0015","first-page":"1","article-title":"Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia","author":"Natarajan","year":"2018","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.leukres.2019.106285_bib0020","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2019.106285_bib0025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"D.M","year":"2006","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.leukres.2019.106285_bib0030","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes TP","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.leukres.2019.106285_bib0035","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2019.106285_bib0040","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"v.R.F","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.leukres.2019.106285_bib0045","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00432-017-2445-z","article-title":"An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase","volume":"143","author":"Steegmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2019.106285_bib0050","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"T.K","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2019.106285_bib0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"16","key":"10.1016\/j.leukres.2019.106285_bib0060","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2019.106285_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-018-0101-5","article-title":"Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy","author":"Eadie","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2019.106285_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.leukres.2016.10.005","article-title":"Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice","volume":"51","author":"da Cunha Vasconcelos","year":"2016","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.leukres.2019.106285_bib0075","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.leukres.2019.106285_bib0080","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"S.N","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.leukres.2019.106285_bib0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.59566\/IJBS.2009.5223","article-title":"Kinetics of BCR-ABL transcripts in imatinib mesylate treated chronic phase CML (CPCML), a predictor of response and progression free survival","volume":"5","author":"E.N.Y","year":"2009","journal-title":"Int. J. Biomed. Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212619307301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:08Z","timestamp":1758934808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212619307301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":17,"alternative-id":["S0145212619307301"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106285","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2019.106285","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106285"}}